The control group’s prevalence of HαT was 4.4% in 180 anonymized sex-matched controls, and 3.9 to 5.0% in 720 patients diagnosed with other myeloid neoplasms (180 AML, 180 MDS, MDS/MPN, 180 MPN and 180 CML), thus comparable to frequencies in the general Caucasian population as already published by other studies [186]. The gene discussed is TMPRSS11D; the disease is myeloproliferative neoplasm.